非小细胞肺癌MET基因变异及其抑制剂靶向治疗进展  

Research progress in targeted therapy of MET gene variation and its inhibitors in non-small cell lung cancer

作　　者：牛娜(综述) 刘震天[2] 钭方芳(审校) NIU Na;LIU Zhentian;TOU Fangfang(Medical College of Nanchang University,Nanchang,Jiangxi 330006,China;Jiangxi Cancer Hospital,Nanchang,Jiangxi 330029,China;Jiangxi Provincial People′s Hospital,Nanchang,Jiangxi 330006,China)

机构地区：[1]南昌大学医学院,江西南昌330006 [2]江西省肿瘤医院,江西南昌330029 [3]江西省人民医院,江西南昌330006

出　　处：《现代医药卫生》2023年第16期2805-2811,共7页Journal of Modern Medicine & Health

摘　　要：间质上皮转化因子(MET)是一种肝细胞生长因子酪氨酸激酶受体。在非小细胞肺癌(NSCLC)中,MET是重要的驱动基因之一,其激活途径多样,并通过多种机制影响肺癌细胞的存活、增殖和侵袭。在NSCLC中最常见的MET基因变异是MET第14号外显子跳跃突变和MET基因扩增,其中继发性MET基因扩增是表皮生长因子受体(EGFR)突变阳性的NSCLC患者经EGFR酪氨酸激酶抑制剂治疗后重要的耐药形式。MET抑制剂在多项临床试验中显示出有效获益。该文就MET在NSCLC中的基因变异类型、检测方法及目前已应用于临床的选择性MET抑制剂靶向治疗进展进行综述。Mesenchymal-epithelial transition factor(MET)is a receptor of liver cell growth factor tyrosinase.In non-small cell lung cancer(NSCLC),the MET is one of the important driver genes with diverse activation pathways and is involved in the survival,proliferation and invasion of lung cancer cells through multiple mechanisms.The most common MET gene variants in NSCLC are MET 14th exon-skipping mutations and MET gene amplification.Secondary MET gene amplification is an important form of drug resistance in patients with epidermal growth factor receptor(EGFR)mutation-positive NSCLC treated with EGFR tyrosine kinase inhibitors.MET inhibitors have shown effective benefits in multiple clinical trials.This article reviewed the types of MET gene variation,detection methods and the latest advances in selective MET inhibitors in the treatment of NSCLC for targeted therapies.

关 键 词：非小细胞肺癌 间质上皮转化因子 靶向治疗 MET抑制剂 

分 类 号：R734.2[医药卫生—肿瘤]